SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for… 2013 · Cochrane Headline outcomes onlyOR 0.92 [0.74, 1.13]9130 participantsModerate